Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 SGX942 (dusquetide) for severe oral mucositis in head and neck cancer chemoradiation
2017-003702-41Phase 3Unknown
- Sponsor
- Soligenix
- Start
- Dec 2017
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of dusquetide in stomatitis, sponsored by Soligenix. Status: unknown.
02
Drugs
dusquetide
03
Conditions
stomatitis
Beyond the preview
Go deeper on 2017-003702-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003702-41.